| Sumario: | The article focuses on the advancements in bioanalysis driven by artificial intelligence (AI), machine learning (ML), and innovative instrumentation, which are enhancing drug development processes. It discusses how AI and ML are increasingly integrated into bioanalytical methods to improve data evaluation, automate processes, and ensure regulatory compliance, while also addressing challenges such as sensitivity and sample size. The article highlights the role of large language models (LLMs) in streamlining documentation and improving workflows, as well as the importance of high-resolution mass spectrometry (HRMS) and other advanced technologies in achieving precise quantification of complex molecules. Additionally, it notes the impact of evolving regulations on bioanalytical practices, emphasizing the need for compliance and adaptation to new standards in the pharmaceutical industry.
|
|---|